Satrum Egg – FDA 483, May 11, 2011

This FDA Form 483 document details observations made during an inspection, indicating deficiencies in the firm's operations.

**Observation 1:** The firm failed to establish adequate procedures for the cleaning and maintenance of equipment. This suggests a lack of documented and implemented processes to ensure equipment is properly cleaned and maintained, which is critical for preventing cross-contamination and ensuring product quality.

**Observation 2:** The firm did not adequately validate the manufacturing process for Drug X. Process validation is a regulatory requirement to ensure that a manufacturing process consistently produces a product meeting its predetermined specifications and quality attributes. The absence of adequate validation indicates a potential risk of inconsistent product quality for Drug X.

**Observation 3:** The firm did not have proper controls in place to prevent contamination of Drug Y. This observation points to a significant deficiency in contamination control strategies, which could lead to compromised product sterility, purity, or safety for Drug Y.

Collectively, these observations highlight issues within the firm's quality system and manufacturing practices, specifically concerning equipment management, process validation, and contamination control. These deficiencies could have significant business and operational implications, potentially leading to product recalls, regulatory actions, and impacts on product availability and market reputation.